1 Divisions of Endocrinology and 2 Geriatric Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Glucose tolerance progressively declines
with age, and there is a high prevalence of type 2 diabetes and
postchallenge hyperglycemia in the older population. Age-related
glucose intolerance in humans is often accompanied by insulin
resistance, but circulating insulin levels are similar to those of
younger people. Under some conditions of hyperglycemic challenge,
insulin levels are lower in older people, suggesting -cell
dysfunction. When insulin sensitivity is controlled for, insulin
secretory defects have been consistently demonstrated in aging humans.
In addition,
-cell sensitivity to incretin hormones may be decreased
with advancing age. Impaired
-cell compensation to age-related
insulin resistance may predispose older people to develop postchallenge
hyperglycemia and type 2 diabetes. An improved understanding of the
metabolic alterations associated with aging is essential for the
development of preventive and therapeutic interventions in this
population at high risk for glucose intolerance.
aged humans; -cell function
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
GLUCOSE TOLERANCE PROGRESSIVELY DECLINES with age, resulting in a high prevalence of type 2 diabetes and impaired glucose tolerance in the older population (21). The interaction of many factors associated with aging likely contributes to the alterations in glucose tolerance in this population. These factors include increased adiposity, decreased physical activity, medications, coexisting illness, and insulin secretory defects associated with the aging process. The mechanism of age-related glucose intolerance is not completely clear. This article will review the epidemiology of age-related glucose intolerance and the effects of aging on insulin secretion in humans.
![]() |
EPIDEMIOLOGY OF AGE-RELATED CHANGES IN GLUCOSE METABOLISM |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
As shown in Fig. 1, according to the
Third National Health and Nutrition Examination Survey (NHANES III)
conducted from 1988 to 1994, the prevalence of type 2 diabetes in
Americans 60-74 yr of age is >20% (22, 41). This
percentage includes cases previously diagnosed by medical history and
those newly diagnosed by fasting glucose or by oral glucose tolerance
testing (OGTT). An additional 20% of this population meets criteria
for impaired glucose tolerance (IGT), defined as a 2-h glucose level
140 mg/dl but <200 mg/dl by OGTT, and a fasting blood glucose not in
the diabetic range (<126 mg/dl) (22). Prevalence data
from 1976 to 1980 from NHANES II for diabetes and IGT in Americans
60-74 yr of age were similar (23); thus the high
prevalence of glucose intolerance in the older population has persisted
over the past two decades. Additional studies of older adults,
including the Cardiovascular Health Study and Honolulu Heart Study,
show that the high prevalence of diabetes and IGT continues in people
over age 75 (46, 43).
|
Isolated postchallenge hyperglycemia (IPH), defined as a 2-h glucose
level 200 mg/dl by OGTT but a fasting glucose level <126 mg/dl, is
particularly common in people over age 60 (6, 11, 46).
Population studies indicate that postchallenge glucose levels increase
with age by ~6-9 mg/dl per decade (4), whereas
fasting glucose levels increase with age by ~1-2 mg/dl per
decade (5). Several studies have examined the impact of
the most recent American Diabetes Association diagnostic criteria on
prevalence rates for diabetes in the older population. Two studies
involving the older US population include the Cardiovascular Health
Study, in which 52% of participants newly diagnosed with diabetes had
IPH (46), and the Rancho Bernardo Study, in which 60% of
older subjects meeting diabetes criteria had IPH (6). In a
large European cohort, 35% of adults aged 60-79 yr and newly
diagnosed with diabetes had IPH (11). Older adults meeting
diagnostic criteria for diabetes (including those with IPH) have
increased risks of fatal cardiovascular disease and all-cause mortality
(6, 11). In addition, all-cause mortality increases as
postchallenge glucose levels rise in people of all ages
(12).
![]() |
EFFECTS OF AGING ON INSULIN SECRETION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Age-related insulin secretory dysfunction may have a role in the
alterations in glucose metabolism with age and may contribute to the
high rates of glucose intolerance in the older population. Many studies
have examined the effects of aging on pancreatic -cell function in
humans, although there is a great deal of variability in the outcomes
of these studies (1). This variability may be due to
multiple factors, including the small magnitude of the age effect, the
use of different measures of insulin secretion, and confounding factors
associated with aging such as obesity, decreased physical activity, and
concomitant insulin resistance. One challenge in studying the time
course of development of abnormal glucose tolerance in any population
is the sensitivity of tests to detect early abnormalities of
-cell
function. The earliest insulin secretory defects in the progression
from normal to abnormal glucose tolerance may be subtle. Thus sensitive
measures of
-cell function are crucial.
![]() |
AGING AND INSULIN SECRETION IN NONDIABETIC HUMANS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
OGTT. Many studies have used insulin levels in the fasting state and in response to an oral glucose load to assess insulin secretion. A delayed insulin response in the 1st h after oral glucose load has been described in older people compared with young adults, despite the older adults having higher (but not diabetic) fasting and postchallenge glucose levels (9). Other studies have noted normal or increased insulin levels in response to oral glucose with advancing age (13, 40).
Confounding factors affecting insulin sensitivity, such as adiposity and aging, may be playing a role in these different results. Cross-sectional data from the Baltimore Longitudinal Study of Aging examined insulin and glucose response in adults ranging in age from 20 to 96 yr. An increased insulin response to oral glucose with advancing age was found in both men and women from 20 to 80 yr of age. However, after adjustments were made for body habitus (and thus indirectly for obesity-related insulin resistance), insulin levels in response to oral glucose load were found to decline significantly with age (34). Although the OGTT is standardized, simple to perform, and widely used in large, epidemiological studies, theIntravenous glucose tolerance test. The frequently sampled intravenous glucose tolerance test (FSIVGTT) provides an assessment of first- and second-phase insulin release as well as insulin sensitivity. Absolute defects in acute insulin response to intravenous glucose related to age alone have not been clearly demonstrated (8, 17, 35), despite older subjects being glucose intolerant (but not to the diabetic range) and insulin resistant compared with younger control subjects.
In a study including subjects with normal glucose tolerance and IGT with an age range of 61-88 yr of age, glucose metabolism as assessed by FSIVGTT was similar in adults >80 yr of age compared with those aged 61-79 yr of age (19). When subjects were classified by glucose tolerance status, older people with IGT were insulin resistant and tended to have lower acute insulin response to glucose and lower glucose effectiveness compared with older people with normal glucose tolerance.Hyperglycemic clamp.
-Cell function can be evaluated with the hyperglycemic clamp
technique, in which plasma glucose levels are increased to the same
extent above basal levels in subjects by means of intravenous glucose
infusions. Previous studies using this method have shown little or no
decrease in insulin secretion with age (3, 14). Bourey et
al. (7) performed 3-h hyperglycemic clamp studies in young
subjects with normal glucose tolerance and in older adults with various
degrees of glucose tolerance. Older subjects with glucose tolerance
comparable to young subjects had similar insulin response during the
hyperglycemic clamp. However, the subgroup of older subjects with mild
glucose intolerance defined as nondiagnostic OGTT or IGT tended to have
increased early insulin response and a decrease in the 3rd-h response.
None of these studies took into account the effect of age-related
insulin resistance on
-cell function.
Pulsatile insulin and arginine stimulation.
Other methods to evaluate -cell function, such as pulsatile insulin
release and the use of nonglucose stimuli such as arginine, have
detected age-related defects in insulin secretion. Normal insulin
secretion is pulsatile and orderly, with both rapid, low-amplitude pulses, which occur every 8-15 min, and ultradian pulses, which have a larger amplitude and occur every 60-140 min
(37). In the fasting state, older subjects have been found
to have more disorderly insulin release, with decreased amplitude and
mass of rapid insulin pulses and reduced frequency of ultradian pulses (31) compared with young subjects. Scheen et al.
(44) evaluated insulin response to a 53-h constant glucose
infusion in weight-matched young and old subjects. The elderly subjects
had decreased pulse amplitude and decreased responsiveness of insulin
secretion to oscillations in glucose. Pulsatile insulin release has
also been assessed in response to a 10-h sustained glucose infusion in
healthy young and old subjects matched for body mass index (BMI)
(32). The old subjects displayed reduced mass and
amplitude of rapid insulin pulses and reduced frequency, amplitude, and
regularity of ultradian pulses compared with the young subjects.
Insulin clearance.
All of the above methods have used peripheral insulin levels as a
measure of the effect of aging on -cell response. Interpretation of
these results may be problematic, as some studies have shown a small
but consistent decrease in insulin clearance in older adults (18,
27, 33). In these studies, insulin clearance rates were compared
in young and old adults with the euglycemic clamp technique and
steady-state insulin infusions. Steady-state insulin plasma levels were
higher in older subjects at each insulin infusion rate, indicative of
decreased clearance of insulin in older subjects. Comparable insulin
levels in old and young people may thus reflect relative insulin
secretory defects in old people in light of diminished insulin
clearance and relative glucose intolerance in this group.
C-peptide kinetics. Pancreatic islet function can also be assessed by C-peptide measurements and kinetics. This approach bypasses the issue of hepatic clearance of insulin and possible changes in insulin clearance with aging, since C-peptide is not metabolized by the liver. Gumbiner et al. (20) used this method to assess insulin secretion in older adults in response to meal and intravenous glucose challenges. In this study, insulin secretory rates were derived from a two-compartment model by using deconvolution of peripheral C-peptide concentrations and incorporating rate constants from bolus injection of biosynthetic human C-peptide. No age differences were found in absolute insulin secretion with 24-h meal profiles or with intravenous glucose challenge by hyperglycemic clamp and stepped glucose infusion. However, this study suggested a decreased relative insulin response to stepped glucose infusion in old subjects when differences in glucose levels and insulin sensitivity between old and young subjects were considered. Endogenous clearance of insulin was also evaluated on the basis of this method. Insulin clearance during basal and mixed-meal conditions was similar in old and young subjects, in contrast to other studies just described that suggested a small decrease in insulin clearance with aging.
Proinsulin.
An increased circulating proinsulin-to-insulin ratio in response to
oral glucose challenge has been described in older adults (45). This was thought to possibly represent a
predisposing factor to the development of glucose intolerance in older
people. Roder et al. (42) also examined the
proinsulin-to-immunoreactive insulin ratio in old and young subjects
matched for BMI in response to intravenous glucose and arginine.
Fasting glucose, fasting insulin, and proinsulin-to-insulin ratio were
similar in both groups. It was felt that -cell dysfunction in older
adults was not associated with increased proinsulin. However, there was
evidence of defective insulin secretion as assessed by fasting insulin levels and acute insulin response to secretagogues in light of the
degree of insulin resistance in the old compared with the young subjects.
Relationship between insulin secretion and insulin resistance in
aging.
Potential explanations for variable results when aging-related defects
in -cell function are assessed include the lack of age
standardization and differences in age-related variables such as
insulin resistance, obesity, and physical activity in young and old
subjects. Findings of similar insulin secretion in young and old
subjects may suggest relative defects in pancreatic
-cell function
in light of concomitant insulin resistance and relative glucose
intolerance in the older population. When young and old subjects are
matched for these variables, reduced
-cell function with aging has
been detected.
Enteroinsular axis and aging.
The enteroinsular axis refers to the glucose-stimulated gut hormones,
or incretin hormones, that potentiate insulin release. Age-related
alteration in the incretin hormones, including glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1), has been of interest as a possible contributing factor to the glucose
intolerance seen with advancing age. Basal GIP levels have been found
to be unchanged with aging (26). GIP and GLP-1 levels in
response to oral glucose have been found to be normal (25,
26) or increased in nonobese (16, 39) and obese
healthy old people (28) compared with young controls. The
hyperglycemic clamp technique combined with oral glucose ingestion has
shown that older people have slightly enhanced GIP response to oral glucose with slightly lower insulin response to endogenous GIP. This
suggests that -cell sensitivity to GIP may be impaired in old people
compared with younger controls (16).
![]() |
INSULIN SECRETION IN OLDER PEOPLE WITH TYPE 2 DIABETES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Numerous studies have investigated glucose metabolism in adults with type 2 diabetes, although relatively few have included people >65 yr of age. Studies of people with type 2 diabetes of all ages have clearly shown impaired insulin secretion with intravenous glucose tolerance testing (36, 38).
Meneilly et al. (29) assessed insulin secretion in lean
and obese older people with normal glucose tolerance and type 2 diabetes by an oral glucose load based on body surface area and the
hyperglycemic clamp technique. Lean older type 2 diabetic subjects were
found to have normal fasting insulin levels, whereas obese older type 2 diabetic subjects had increased fasting insulin levels. Obese diabetic
subjects had greater insulin responses to oral glucose than lean
diabetic subjects. The obese diabetic subjects also had similar insulin
responses compared with obese age-matched controls, but these responses
were clearly impaired given the much higher glucose levels during OGTT
in the diabetic subjects. In confirmation of this defective insulin
secretion, both lean and obese older diabetic subjects had absent
first-phase insulin release to intravenous glucose with the
hyperglycemic clamp, as in younger diabetic patients. Lean older
diabetic subjects had marked defects in second-phase insulin secretion.
Obese older diabetic subjects had second-phase insulin secretion
similar to control subjects, but this likely reflects -cell
dysfunction in light of increased insulin resistance in the diabetic subjects.
![]() |
CONCLUSIONS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Glucose tolerance progressively declines with age, and there is a high prevalence of diabetes and IGT in the older population. More than 40% of Americans 65 yr and older meet diagnostic criteria for type 2 diabetes or IGT (22, 41). IPH is particularly common in this age group (6, 11, 46). Individuals with type 2 diabetes (including IPH) or IGT have associated increased morbidity and mortality (5, 6, 43).
As shown in Fig. 2, a model of normal
adaptation to insulin resistance of any cause and at any age may
include compensatory hyperinsulinemia to maintain normal glucose
metabolism. In contrast, a model of age-related hyperglycemia is
displayed in Fig. 3. The interaction of
many diabetes risk factors associated with aging is likely to
contribute to the development of age-related glucose intolerance and
increased insulin resistance. On average, studies of the effect of
aging on insulin secretion suggest that relative insulin secretory
defects are associated with advancing age in light of increased insulin
resistance and possible decreased insulin clearance with aging. When
insulin sensitivity is controlled for, insulin secretory defects have
been consistently demonstrated in aging humans. In addition, -cell
sensitivity to incretin hormones may be decreased with advancing age.
Impaired
-cell compensation to age-related insulin resistance may
predispose older people to develop IGT and type 2 diabetes. Sensitive
measures of
-cell function are essential to further delineate the
effects of normal aging on insulin secretion. Impaired
-cell
compensation to age-related insulin resistance may predispose older
people to develop IGT and type 2 diabetes. Sensitive measures of
-cell function are essential to further delineate the effects of
normal aging on insulin secretion.
|
|
Recent diabetes prevention studies, including the Diabetes Prevention Program (DPP) in the US and the STOP-NIDDM trial in Canada and Europe, have enrolled older adults with IGT. In the DPP, 20% of 3,234 total subjects were 60 yr of age or older (15). In this trial, both lifestyle changes and metformin treatment significantly reduced the incidence of diabetes by 58 and 31%, respectively (compared with placebo). The lifestyle intervention was particularly effective in older people, with a 71% reduction in diabetes incidence (in contrast to an 11% reduction with metformin in this age group). In STOP-NIDDM, 47% of 1,364 subjects were >55 yr of age, with a range of 40-70 yr (10). In this study, acarbose treatment decreased the progression to diabetes by 25% compared with placebo and was effective across the age range. Thus lifestyle and pharmacological intervention to prevent diabetes in people with IGT (including the older population) is effective. Because postchallenge hyperglycemia is particularly common in older people, screening and therapy of this high-risk group should be reassessed. A better understanding of the metabolic alterations associated with aging is important for the continued development of preventive and therapeutic strategies for this population at high risk for the development of diabetes.
![]() |
FOOTNOTES |
---|
Address for reprint requests and other correspondence: J. B. Halter, Univ. of Michigan, 1111 CCGC Bldg., 1500 E. Medical Center Dr., Ann Arbor, MI 48109-0926 (E-mail: jhalter{at}umich.edu).
A. M. Chang, University of Michigan, 3920 Taubman Ctr., 1500 E. Medical Center Dr., Ann Arbor, MI 48109-0354 (E-mail: annchang{at}umich.edu).
10.1152/ajpendo.00366.2002
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Adelman, R.
Secretion of insulin during aging.
J Am Geriatr Soc
37:
983-990,
1989[ISI][Medline].
2.
Ahren, B,
and
Pacini G.
Age-related reduction in glucose elimination is accompanied by reduced glucose effectiveness and increased hepatic insulin extraction in man.
J Clin Endocrinol Metab
83:
3350-3356,
1998
3.
Andres, R.
Aging and diabetes.
Med Clin North Am
55:
835-846,
1971[ISI][Medline].
4.
Andres, R.
Aging, diabetes, and obesity: standards of normality.
Mt Sinai J Med
48:
489-295,
1981[ISI][Medline].
5.
Andres, R,
and
Tobin JD.
Aging and the disposition of glucose.
Adv Exp Biol Med
61:
239-249,
1975[Medline].
6.
Barrett-Connor, E,
and
Ferrara A.
Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men.
Diabetes Care
21:
1236-1239,
1998[Abstract].
7.
Bourey, RE,
Kohrt WM,
Kirwan JP,
Staten MA,
King DS,
and
Holloszy JO.
Relationship between glucose tolerance and glucose-stimulated insulin response in 65-year-olds.
J Gerontol
48:
M122-M127,
1993[ISI][Medline].
8.
Chen, M,
Bergman RN,
Pacini G,
and
Porte D, Jr.
Pathogenesis of age-related glucose intolerance in man: insulin resistance and decreased -cell function.
J Clin Endocrinol Metab
60:
13-20,
1985[Abstract].
9.
Chen, M,
Halter JB,
and
Porte D, Jr.
Pathogenesis of age-related glucose intolerance of the elderly.
J Am Geriatr Soc
35:
417-424,
1987[ISI][Medline].
10.
Chiasson, JL,
Josse RG,
Gomis G,
Hanefeld M,
Karasik A,
and
Laakso M.
Acarbose for the prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial.
Lancet
359:
2072-2077,
2002[ISI][Medline].
11.
DECODE study group.
Consequences of the new diagnostic criteria for diabetes in older men and women.
Diabetes Care
22:
1667-1671,
1999[Abstract].
12.
DECODE study group.
Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria.
Lancet
354:
617-621,
1999[ISI][Medline].
13.
DeFronzo, R.
Glucose intolerance and aging.
Diabetes Care
4:
493-501,
1981[Abstract].
14.
DeFronzo, RA.
Glucose intolerance and aging: evidence for tissue insensitivity to insulin.
Diabetes
28:
1095-1101,
1979[ISI][Medline].
15.
Diabetes Prevention Program Research Group.
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
N Engl J Med
346:
393-403,
2002
16.
Elahi, D,
Andersen DK,
Muller DC,
Tobin JD,
Brown JC,
and
Andres R.
The enteric enhancement of glucose-stimulated insulin release: the role of GIP in aging, obesity, and non-insulin-dependent diabetes mellitus.
Diabetes
33:
950-957,
1984[Abstract].
17.
Feldman, JM,
and
Plonk JW.
Effect of age on intravenous glucose tolerance and insulin secretion.
J Am Geriatr Soc
24:
1-3,
1976[ISI][Medline].
18.
Fink, RI,
Reyers RR,
Kolterman OG,
and
Olefsky JM.
The metabolic clearance of insulin and the feedback inhibition of insulin secretion are altered with aging.
Diabetes
34:
275-280,
1985[Abstract].
19.
Garcia, GV,
Freeman RV,
Supiano MA,
Smith MJ,
Galecki AT,
and
Halter JB.
Glucose metabolism in older adults: a study including subjects more than 80 years of age.
J Am Geriatr Soc
45:
813-817,
1997[ISI][Medline].
20.
Gumbiner, B,
Polonsky KS,
Beltz WF,
Wallace P,
Brechtel G,
and
Fink RI.
Effects of aging on insulin secretion.
Diabetes
38:
1549-1546,
1989[Abstract].
21.
Halter, JB.
Carbohydrate metabolism.
In: Handbook of Physiology. Aging. Bethesda, MD: Am. Physiol. Soc, 1995, sect. 11, chapt. 7, p. 119-145.
22.
Harris, MI,
Flegal KM,
Cowie CC,
Eberhardt MS,
Goldstein DE,
Little RR,
Wiedmeyer HS,
and
Byrd-Holt DD.
Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U. S. adults: The third National Health and Nutrition Examination Survey, 1988-1994.
Diabetes Care
21:
518-524,
1998[Abstract].
23.
Harris, MI,
Hadden WC,
Knowler WC,
and
Bennett PH.
Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U. S. population aged 30 to 74 yr.
Diabetes
36:
523-534,
1987[Abstract].
24.
Kahn, SE,
Larson VG,
Schwartz RS,
Beard JC,
Cain KC,
Fellingham GW,
Stratton JR,
Cerqueira MD,
and
Abrass IB.
Exercise training delineates the importance of B-cell dysfunction to the glucose intolerance of human aging.
J Clin Endocrinol Metab
74:
1336-1342,
1992[Abstract].
25.
Korosi, J,
McIntosh CHS,
Pedersen RA,
Demuth HU,
Habener JF,
Gingerich R,
Egan JM,
Elahi D,
and
Meneilly GS.
Effect of aging and diabetes on the enteroinsular axis.
J Gerontol Med Sci
56A:
M575-M579,
2001
26.
McConnell, JG,
Alam MJ,
O'Hare MM,
Buchanen KD,
and
Stout RW.
The effect of age and sex on the response of enteropancreatic polypeptide to oral glucose.
Age Ageing
12:
54-62,
1993[Abstract].
27.
McGuire, EA,
Tobin JD,
Berman M,
and
Andres R.
Kinetics of native insulin in diabetic, obese, and aged men.
Diabetes
28:
110-120,
1979[Abstract].
28.
Meneilly, GS,
Demuth HU,
McIntosh CHS,
and
Pederson RA.
Effect of ageing and diabetes on glucose-dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose.
Diabet Med
17:
346-350,
2000[ISI][Medline].
29.
Meneilly, GS,
Elliott T,
Tessier D,
Hards L,
and
Tildesley H.
NIDDM in the elderly.
Diabetes Care
19:
1320-1324,
1997[Abstract].
30.
Meneilly, GS,
Ryan AS,
Minaker K,
and
Elahi D.
The effect of age and glycemic level on the response of the -cell to glucose-dependent insulinotropic polypeptide and peripheral tissue sensitivity to endogenously released insulin.
J Clin Endocrinol Metab
83:
2925-2932,
1998
31.
Meneilly, GS,
Ryan AS,
Veldhuis JD,
and
Elahi D.
Increased disorderliness of basal insulin release, attenuated insulin secretory burst mass, and reduced ultradian rhythmicity of insulin secretion in older individuals.
J Clin Endocrinol Metab
82:
4088-4093,
1997
32.
Meneilly, GS,
Veldhuis JD,
and
Elahi D.
Disruption of the pulsatile and entropic modes of insulin release during and unvarying glucose stimulus in elderly individuals.
J Clin Endocrinol Metab
84:
1938-1943,
1999
33.
Minaker, KL,
Rowe JW,
Tonino R,
and
Pallotta JA.
Influence of age on clearance of insulin in man.
Diabetes
31:
851-855,
1982[Abstract].
34.
Muller, DC,
Elahi D,
Tobin JD,
and
Andres R.
Insulin response during the oral glucose tolerance test: the role of age, sex, body fat and the pattern of fat distribution.
Aging Clin Esp Res
8:
13-21,
1996.
35.
Palmer, JP,
and
Ensinck JW.
Acute-phase insulin secretion and glucose tolerance in young and aged normal men and diabetic patients.
J Clin Endocrinol Metab
41:
498-503,
1975[Abstract].
36.
Pfeifer, MA,
Halter JB,
and
Porte D, Jr.
Insulin secretion in diabetes mellitus.
Am J Med
70:
579-588,
1981[ISI][Medline].
37.
Polonsky, KS,
Given BD,
and
Van Cauter E.
Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects.
J Clin Invest
81:
442-448,
1988[ISI][Medline].
38.
Porte, D, Jr.
Banting lecture 1990. Beta-cells in type II diabetes mellitus.
Diabetes
40:
166-180,
1991[Abstract].
39.
Ranganath, L,
Sedgwick I,
Morgan L,
Wright J,
and
Marks V.
The ageing entero-insular axis.
Diabetologia
41:
1309-1313,
1998[ISI][Medline].
40.
Reaven, GM,
and
Reaven EP.
Age, glucose intolerance, and non-insulin dependent diabetes mellitus.
J Am Geriatr Soc
33:
286-290,
1985[ISI][Medline].
41.
Resnick, HE,
Harris MI,
Brock DB,
and
Harris TB.
American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles.
Diabetes Care
23:
176-180,
2000[Abstract].
42.
Roder, ME,
Schwartz RS,
Prigeon RL,
and
Kahn SE.
Reduced pancreatic B cell compensation to the insulin resistance of aging: impact on proinsulin and insulin levels.
J Clin Encrinol Metab
85:
2275-2280,
2000
43.
Rodriguez, BL,
Curb JD,
Burchfiel CM,
Huang B,
Sharp D,
Ye Lu G,
Fujimoto W,
and
Katsuhiko Y.
Impaired glucose tolerance, diabetes, and cardiovascular disease risk factor profiles in the elderly: the Honolulu Heart Program.
Diabetes Care
19:
587-190,
1996[Abstract].
44.
Scheen, AJ,
Sturis J,
Polonsky KS,
and
Van Cauter E.
Alterations in the ultradian oscillations of insulin secretion and plasma glucose in aging.
Diabetologia
39:
564-572,
1996[ISI][Medline].
45.
Shimuzu, M,
Kawazu S,
Tomono S,
Ohno T,
Utsugi T,
Kato N,
Ishii C,
Ito Y,
and
Murata K.
Age-related alteration of pancreatic beta-cell function: increased proinsulin and proinsulin-to-insulin molar ratio in elderly, but not in obese, subjects without glucose intolerance.
Diabetes Care
19:
8-11,
1996[Abstract].
46.
Wahl, PW,
Savage PJ,
Psaty BM,
Orchard TJ,
Robbins JA,
and
Tracy RP.
Diabetes in older adults: comparison of 1997 American Diabetes Association classification of diabetes mellitus with 1985 WHO classification.
Lancet
352:
1012-1015,
1998[ISI][Medline].